Midostaurin (Rydapt) maintenance therapy for acute myeloid leukemia (AML)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Regimen in use at


Study Evidence Efficacy
Stone et al. 2017 (RATIFY) Non-randomized portion of RCT CR rate: 59% after induction

Preceding treatment


28-day cycle for up to 13 cycles (1 year)


  1. RATIFY: Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. Epub 2017 Jun 23. link to original article link to PMC article contains dosing details in manuscript PubMed